Understanding this will be important if we are to use Topo VI as an antibiotic target in those bacteria that have the enzyme.

The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...

Like quinolone-based antibiotics that have been in use since the 1960s, gepotidacin acts on bacterial type IIA topoisomerases, DNA-unwinding enzymes. It originates however from a structurally ...

The FDA has approved the drug for use in women and girls over the age of 12 who suffer from uncomplicated urinary tract ...

The FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...

Gepotidacin has an entirely new mechanism of action, inhibiting DNA replication via two different type II topoisomerase enzymes, which should make it harder for pathogens to develop resistance.

Gepotidacin inhibits DNA replication via two different type II topoisomerase enzymes, and its dual mode of action should make it harder for pathogens to develop resistance. Its approval is a rare ...

Levofloxacin 5mg/mL; soln for slow IV infusion; preservative-free. Levofloxacin inhibits bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...